← Eichor
Study identifier: NCT06111417 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners

Condition: Breast Cancer  ·  Sponsor: Centre Georges Francois Leclerc

PhaseN/A
Planned participants150
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The time taken to obtain the results of germline mutations in BRCA1 and BRCA2 has become a major issue in adapting the therapeutic management of patients, particularly those with breast cancer. The time taken to obtain the results of BRCA1/2 tests in routine laboratories with a view to personalised treatment can range from a few weeks to a few months. The waiting time required to obtain results is likely to cause stress and anxiety in cancer patients. The investigators hypothesise that ultra-rapid testing can reduce anxiety about patients' genetic status and improve their mental well-being. The main objective of this project is to compare the results obtained with an ultra-fast kit developed by O.N.T with those obtained with the current gold standard, NGS sequencing.

This description comes directly from the study's public registry record.

Talk to the study team

Manon REDA, Dr  ·  03.80.73.75.00  ·  mreda@cgfl.fr

Emilie REDERSTORFF, Project Manager  ·  03 45 34 81 16  ·  erederstorff@cgfl.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Centre Georges-François LeclercDijon, FranceRecruiting
Institut RafaëlLevallois-Perret, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06111417